Esperion Therapeutics, Inc.
ESPR
$2.51
-$0.21-7.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 403.14M | 303.80M | 268.13M | 259.57M | 332.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 403.14M | 303.80M | 268.13M | 259.57M | 332.31M |
| Cost of Revenue | 177.08M | 171.90M | 144.17M | 135.46M | 114.84M |
| Gross Profit | 226.06M | 131.90M | 123.96M | 124.12M | 217.48M |
| SG&A Expenses | 165.79M | 161.28M | 159.41M | 164.08M | 163.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 342.86M | 333.18M | 303.57M | 299.54M | 277.91M |
| Operating Income | 60.27M | -29.38M | -35.45M | -39.96M | 54.40M |
| Income Before Tax | -20.84M | -105.83M | -104.02M | -153.22M | -51.75M |
| Income Tax Expenses | 1.84M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.68 | -105.83 | -104.02 | -153.22 | -51.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.68M | -105.83M | -104.02M | -153.22M | -51.75M |
| EBIT | 60.27M | -29.38M | -35.45M | -39.96M | 54.40M |
| EBITDA | 60.38M | -29.27M | -35.34M | -39.88M | 54.50M |
| EPS Basic | -0.17 | -0.54 | -0.53 | -0.79 | -0.23 |
| Normalized Basic EPS | -0.10 | -0.33 | -0.33 | -0.32 | 0.04 |
| EPS Diluted | -0.21 | -0.54 | -0.53 | -0.80 | -0.25 |
| Normalized Diluted EPS | -0.13 | -0.33 | -0.33 | -0.32 | 0.01 |
| Average Basic Shares Outstanding | 831.09M | 789.98M | 784.17M | 775.42M | 748.55M |
| Average Diluted Shares Outstanding | 878.98M | 789.98M | 784.17M | 775.42M | 768.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |